Hypoparathyroidism, Hypothyroidism and Thrombocytopenia: Rare Constellation of Fahr’s Syndrome

Nilma Malik\textsuperscript{a,b}, Vishwanath Pattana, Qiang Nai\textsuperscript{a}, Abdalla Yousif\textsuperscript{a}

Abstract

Fahr’s syndrome is a rare progressive unremitting neurological disorder, characterized by abnormal bilaterally symmetric brain calcifications. It is associated with various endocrinopathies such as hypothyroidism, hypoparathyroidism and hypocalcemia. This case opens up a new horizon of thought process, as it illustrates the clinical presentation of Fahr’s syndrome with thrombocytopenia never reported before. It especially emphasizes on the diagnostic significance of combination of thrombocytopenia with seizures in Fahr’s, as this coupling can result in fatal intracranial hemorrhage if timely seizure management is not initiated.

Keywords: Hypoparathyroidism; Hypothyroidism; Thrombocytopenia

Introduction

Fahr’s syndrome or bilateral striatopallidodentate calcinosis is a rare progressive neurological disorder which is characterized by abnormal extraosseous calcifications especially involving the brain paranchyma. It has a wide spectrum of clinical presentation but most cases manifest with tetany, seizures, dysarthria, increased intracranial pressure, papilledema, soft tissue calcification, blood dyscrasias, dry hair, alopecia, dental dysplasia, caries and predisposition to Moniliases [1] and extra-pyramidal symptoms.

Prompt recognition of combination of thrombocytopenia with seizures in Fahr’s syndrome is crucial as timely treatment can have significant morbidity and mortality benefits.

Case Report

A 51-year-old female presented with an episode of tonic clonic seizures preceded by an aura characterized by spasms of her hands. She denied stool or urinary incontinence, post-ictial confusion, fever or headaches. She complained of weakness and tingling in her body, cold intolerance and memory loss. Her family history was significant for intellectual disability in sister. On physical examination, pulse was 88/min, blood pressure was 111/76 mm Hg, RR was 16/min and T was 98 °F. Patient was alert but lethargic. There was no thyromegaly or nuchal rigidity. Her deep tendon reflexes showed delayed relaxation phase. Labs were significant for platelets 97,000/μL, calcium 0.28 mmol/L, ionized Ca 0.59 mmol/L, albumin 4.2 g/dL, phosphorous 6.7 mmol/L, Mg 1.4 mg/L, TSH 21.82 ng/dL, UDS negative, and CT of head showed symmetric calcification involving the basal ganglia, corona radiata, centrum semiovale, subcortical white matter and cerebellar hemispheres bilaterally (Fig. 1A, B). Further investigations revealed PTH 3 pg/mL, Vit-D-1,25-OH 21 ng/mL, T3 64 ng/dL and T4 0.63 ng/dL. Urine Ca and heavy metal screening was negative. Cortisol, Ldh, lactic acid and RPR were normal. Thyroid and parathyroid ultrasonography was normal. Bone imaging revealed marrow calcifications. The patient was diagnosed with Fahr’s syndrome and was treated with IV calcium, vitamin D and phosphate binder.

Discussion

Fahr’s syndrome is a rare neurological disorder with a prevalence of < 1/1,000,000 per population [2]. It is most commonly transmitted as an autosomal dominant trait, but may also be passed on as an autosomal recessive trait or occur sporadically. It typically manifests in third to fourth decades of life. It is associated with various endocrinopathies especially hypoparathyroidism. Mutations in SLC20A2, encoding the type II sodium-dependent phosphate transporter 2 (PiT2) is proposed [3]. NaPi-II proteins in the kidney and intestine contribute to hyperphosphatemia by modulating the excretion and absorption of phosphorous [4]. The combina-
tion of hypoparathyroidism, hyperphosphatemia and vitamin D-mediated impaired Ca absorption causes hypocalcemia and disrupted bone homeostasis. This abnormal homeostasis leads to defective iron transport, free radical production and tissue damage leading to extraosseous calcification. Fahr’s disease presents clinically with tetany, convulsions, intellectual disabilities, dementia, spastic paralysis, features of Parkinson’s disease, choreothetotic-type movement disturbance [5, 6] and abnormal calcification in brain and bone marrow which possibly causes thrombocytopenia, as in our patient. The psychiatric symptoms of Fahr cannot be explained by any other particular disorder of the calcium phosphorus metabolism or any other disease [7]. Pathophysiology of psychosis in Fahr remains unknown, though previous studies have found a decreased cerebral perfusion matching the distribution of calcification in the cortex, which may reflect secondary deficits.

The differential diagnosis of Fahr includes but is not limited to Parkinson’s disease, Huntington’s disease, progressive supranuclear palsy, Wilson’s disease, spasmodic torticollis, oligodendroglioma, lowgrade astrocytoma and arteriovenous malformation. Therefore Fahr’s disease is a diagnosis of exclusion [8, 9].

There is no cure for Fahr’s syndrome, which worsens over time, nor is there a standard course of treatment. The process of calcification cannot be stopped or reversed. Treatment is therefore symptomatic. Prognosis of Fahr’s syndrome is variable and often poor.

Conclusion

It is thus imperative to recognize thrombocytopenia in Fahr’s syndrome especially in patients with seizures. Concern arises as in background of pre-existing friable intracranial tissue and seizures this thrombocytopenia may lead to fatal spontaneous intracranial hemorrhage. Therefore appropriate seizure management with close monitoring should be persuaded in these patients.

References